CoChat

Efficacy of adjunctive d-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

D-Cycloserine is a partial agonist at the glycine site of the N-methyl-D-aspartate (NMDA) receptor. Results have been inconsistent in trials on the efficacy of D-Cycloserine in patients with schizophrenia. We examined the efficacy of D-Cycloserine against negative and cognitive symptoms (primary and co-primary outcomes). Secondary outcomes were efficacy of D-Cycloserine against positive symptoms and the examination of early treatment outcomes. A systematic literature search was carried out using following selection criteria: Population = Patients with Schizophrenia; Intervention = Trials using D-Cycloserine either as monotherapy or adjuvant therapy; Comparison = Placebo or active comparator; Outcome = Change in negative symptoms, cognitive symptoms and positive symptoms; Study design = Randomized controlled trials with parallel design. We used the Cochrane Collaboration tool for risk of bias for study quality appraisal. Effect sizes for trials were calculated separately for negative, positive and cognitive symptom dimensions using the DerSimonian-Laird random effects model. Seven studies (pooled N = 413) provided data for meta-analysis. The pooled Standardized Mean Difference (SMD) for negative, cognitive, and positive symptom change scores were - 0.32 (95% CI, - 0.75 to 0.11), - 0.05 (95% CI, - 0.91 to 0.81), and - 0.08 (95% CI, - 0.37 to 0.20), respectively. No significant improvement was noted with regard to early outcome. I 2 values for heterogeneity were 61%, 67%, and 0% for studies assessing negative, cognitive, and positive symptom ratings, respectively. D-Cycloserine did not exhibit significant efficacy in treating negative, cognitive, or positive symptoms of schizophrenia at either study-defined endpoint (4-36 weeks) or at four weeks (early outcome).

Overview

Integrity signals

Registry

Crossref · 10.1007/s00702-020-02292-x

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Cited by

See all 16

Metadata

Authors
Kuppili, P. P., Menon, V., Sathyanarayanan, G., Sarkar, S., & Andrade, C.
Affiliations
  • Black Country Healthcare NHS Foundation Trust (GB)
  • Jawaharlal Institute of Post Graduate Medical Education and Research (IN)
  • All India Institute of Medical Sciences (IN)
  • National Institute of Mental Health and Neurosciences (IN)
Corresponding author
Menon, Vikas
Venue
Journal of Neural Transmission
Published
2021-01-13
Volume
128
Issue
2
Pages
253-262
ISSN
  • 0300-9564 (ISSN-L)
  • 1435-1463
OpenAlex
W3120509113
Cited by
16
References
40
Citations by year
2026: 3 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 3 · 2021: 1
FWCI
0.36
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Journal of Neural Transmission (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
D-cycloserine, schizophrenia, adjunctive therapy, NMDA receptor glycine site, negative symptoms, cognitive symptoms, positive symptoms, early treatment outcomes, treatment efficacy
MeSH terms
Cycloserine, Drug Therapy, Combination, Humans, Schizophrenia, Antipsychotic Agents, Randomized Controlled Trials as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of adjunctive d-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1007/s00702-020-02292-x
The paper
Kuppili, P. P., Menon, V., Sathyanarayanan, G., Sarkar, S., & Andrade, C. (2021). Efficacy of adjunctive d-Cycloserine for the treatment of schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Journal of Neural Transmission. https://doi.org/10.1007/s00702-020-02292-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.